Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Biomed Industries plans to launch a stage III clinial trial (NCT06891234) involving 2000 obese patients treated for 52 weeks to evaluate the long-term efficacy, safety, and impact on cardiovascular outcomes of NA-931 peptide
A recent meta-analysis evaluating the effects of GLP-1 RAs on depression found that these agents did not increase the risk of depression and may reduce depression scores [46]
The trial results noted minor improvement exhibited in the subjects cholesterol profiles and glucose tolerance levels
The drug can cross the blood-brain barrier (BBB) and activate GLP-1R in the CNS [49, 50], thus producing neuroprotective and anti-inflammatory effects [50,51,52,53,54,55]
US$ 23.29
US$ 24.73
/assets/images/provider/photos/1922393.jpg)
US$ 24.91
US$ 26.50
US$ 20.60
US$ 24.52
US$ 22.46
